After almost one year of intense global struggle with SARS-CoV-2 since its first report in Dec. 2019, 1 the introduction of several vaccines for COVID-19 prevention has revived hopes in many people around the world. Several vaccines already approved or started to use in different countries are mostly developed based on the spike antigens of SARS-CoV-2, which not only is involved in cell receptor recognition and virulence, 2 but also is very antigenic. 3 The FDA or/and EMA approved vaccines include BNT162b2 (Pfizer and BioNTech), mRNA-1273 (Moderna, USA), AZD1222 (Oxford-AstraZeneca), Janssen COVID-19 Vaccine (Johnson & Johnson). Sputnik V (Gamaleya, Russia), BBIBP-CorV (Sinopharm, China), and CoronaVac (Sinovac, China) are accepted for use in some countries as well. Several others are also in Phase III clinical trials, which might be added to this list soon, such as NVX-CoV2373 (Novavax, USA), Ad5-nCoV (CanSinoBIO, China), and some others. The different approaches and platforms used in these vaccines have led to their varied performances, storage conditions, and prices. Though, the efficacy of these vaccines, despite some variations, are mostly far above the previous expectations; and the benefit of COVID-19 vaccination has been already reported in some countries based on the need for mechanical ventilation, as a sign of severe disease...